(Tonix) Shares of Tonix Pharmaceuticals rose more than 46% on Wednesday after being issued a patent for its vaccine against smallpox and monkeypox.
Tonix said that its TNX-801 vaccine against monkeypox and smallpox earned a patent by the US Patent and Trademark Office on May 31, 2022.
Tonix CEO Seth Lederman described TNX-801 as a horsepox-based live virus vaccine currently in development. He says the patent is important for the company in expanding its pipeline of vaccines for tackling novel pathogens.
The new patent is expected to offer Tonix US market exclusivity until 2037. The patent excludes potential term extensions or adjustments.
